Cinacalcet lowering of serum fibroblast growth factor-23 concentration may be independent from serum Ca, P, PTH and dose of active vitamin D in peritoneal dialysis patients: A randomized controlled study

BMC Nephrology

Volumn 14, Issue 1, 2013, Pages

  Kim, Hyo Jin ^a   Kim, Hyunsuk ^a   Shin, Nara ^a   Na, Ki Young ^b   Kim, Yong Lim ^c   Kim, Daejung ^d   Chang, Jae Hyun ^e   Song, Young Rim ^f   Hwang, Young Hwan ^g   Kim, Yon Su ^a   Ahn, Curie ^a   Lee, Joongyub ^h   Oh, Kook Hwan ^a  

^a Seoul National University   (South Korea)

^b Seoul National University Bundang Hospital   (South Korea)

^c Kyungpook National University   (South Korea)

^d Sungkyunkwan University   (South Korea)

^e Gachon University College of Medicine   (South Korea)

^f Hallym University   (South Korea)

^g Eulji University   (South Korea)

^h Seoul National University Hospital   (South Korea)

Author keywords

Cinacalcet; Fibroblast growth factor 23; Peritoneal dialysis

Indexed keywords

ALBUMIN; ALFACALCIDOL; CALCITRIOL; CALCIUM; CINACALCET; FIBROBLAST GROWTH FACTOR 23; PARATHYROID HORMONE; PARICALCITOL; PHOSPHORUS;

ADULT; AGED; ARTICLE; CONSTIPATION; CONTROLLED STUDY; DIARRHEA; DRUG DOSE INCREASE; DRUG EFFECT; DRUG INDUCED HEADACHE; DRUG SAFETY; DYSPEPSIA; FEMALE; HEMODIALYSIS PATIENT; HUMAN; HYPOCALCEMIA; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NAUSEA AND VOMITING; OPEN STUDY; OUTCOME ASSESSMENT; PERITONEAL DIALYSIS; PROTEIN BLOOD LEVEL; RANDOMIZED CONTROLLED TRIAL; SECONDARY HYPERPARATHYROIDISM; SKIN TINGLING; TREATMENT OUTCOME; WEAKNESS;

ADULT; AGED; BIOLOGICAL MARKERS; CALCIUM; FEMALE; FIBROBLAST GROWTH FACTORS; HUMANS; MALE; MIDDLE AGED; NAPHTHALENES; PARATHYROID HORMONE; PERITONEAL DIALYSIS; PHOSPHORUS; VITAMIN D;

EID: 84878004438     PISSN: None     EISSN: 14712369     Source Type: Journal    
DOI: 10.1186/1471-2369-14-112     Document Type: Article

References (25)

1. Klotho converts canonical FGF receptor into a specific receptor for FGF23. Urakawa I, Yamazaki Y, Shimada T, Iijima K, Hasegawa H, Okawa K, Fujita T, Fukumoto S, Yamashita T, Nature 2006 444 770 774 10.1038/nature05315 17086194
2. Mutation of the mouse klotho gene leads to a syndrome resembling ageing. Kuro-o M, Matsumura Y, Aizawa H, Kawaguchi H, Suga T, Utsugi T, Ohyama Y, Kurabayashi M, Kaname T, Kume E, Iwasaki H, Iida A, Shiraki-Iida T, Nishikawa S, Nagai R, Nabeshima YI, Nature 1997 390 45 51 10.1038/36285 9363890
3. Human fibroblast growth factor-23 mutants suppress Na+-dependent phosphate co-transport activity and 1alpha,25-dihydroxyvitamin D3 production. Saito H, Kusano K, Kinosaki M, Ito H, Hirata M, Segawa H, Miyamoto K, Fukushima N, J Biol Chem 2003 278 2206 2211 10.1074/jbc.M207872200 12419819
4. FGF-23 is a potent regulator of vitamin D metabolism and phosphate homeostasis. Shimada T, Hasegawa H, Yamazaki Y, Muto T, Hino R, Takeuchi Y, Fujita T, Nakahara K, Fukumoto S, Yamashita T, J Bone Miner Res 2004 19 429 435 15040831
5. Fibroblast growth factor 23 is elevated before parathyroid hormone and phosphate in chronic kidney disease. Isakova T, Wahl P, Vargas GS, Gutierrez OM, Scialla J, Xie H, Appleby D, Nessel L, Bellovich K, Chen J, Hamm L, Gadegbeku C, Horwitz E, Townsend RR, Anderson CA, Lash JP, Hsu CY, Leonard MB, Wolf M, Kidney Int 2011 79 1370 1378 10.1038/ki.2011.47 21389978
6. Fibroblast growth factor 23 and left ventricular hypertrophy in chronic kidney disease. Gutierrez OM, Januzzi JL, Isakova T, Laliberte K, Smith K, Collerone G, Sarwar A, Hoffmann U, Coglianese E, Christenson R, Wang TJ, deFilippi C, Wolf M, Circulation 2009 119 2545 2552 10.1161/CIRCULATIONAHA.108. 844506 19414634
7. Fibroblast growth factor 23: a possible cause of left ventricular hypertrophy in hemodialysis patients. Hsu HJ, Wu MS, Am J Med Sci 2009 337 116 122 10.1097/MAJ.0b013e3181815498 19214027
8. The phosphatonin fibroblast growth factor 23 links calcium-phosphate metabolism with left-ventricular dysfunction and atrial fibrillation. Seiler S, Cremers B, Rebling NM, Hornof F, Jeken J, Kersting S, Steimle C, Ege P, Fehrenz M, Rogacev KS, Scheller B, Bohm M, Flister D, Heine GH, Eur Heart J 2011 32 2688 2696 10.1093/eurheartj/ehr215 21733911
9. Serum intact FGF23 associate with left ventricular mass, hypertrophy and geometry in an elderly population. Mirza MA, Larsson A, Melhus H, Lind L, Larsson TE, Atherosclerosis 2009 207 546 551 10.1016/j.atherosclerosis.2009.05. 013 19524924
10. Fibroblast growth factor 23 (FGF23) predicts progression of chronic kidney disease: the mild to moderate kidney disease (MMKD) study. Fliser D, Kollerits B, Neyer U, Ankerst DP, Lhotta K, Lingenhel A, Ritz E, Kronenberg F, Kuen E, Konig P, Kraatz G, Mann JF, Muller GA, Kohler H, Riegler R, J Am Soc Nephrol 2007 18 2600 2608 10.1681/ASN.2006080936 17656479
11. Fibroblast growth factor 23 and risks of mortality and end-stage renal disease in patients with chronic kidney disease. Isakova T, Xie H, Yang W, Xie D, Anderson AH, Scialla J, Wahl P, Gutierrez OM, Steigerwalt S, He J, Schwartz S, Lo J, Ojo A, Sondheimer J, Hsu CY, Lash J, Leonard M, Kusek JW, Feldman HI, Wolf M, JAMA 2011 305 2432 2439 10.1001/jama.2011.826 21673295
12. Effects of cinacalcet and concurrent low-dose vitamin D on FGF23 levels in ESRD. Wetmore JB, Liu S, Krebill R, Menard R, Quarles LD, Clin J Am Soc Nephrology 2010 5 110 116 10.2215/CJN.03630509
13. Cinacalcet treatment and serum FGF23 levels in haemodialysis patients with secondary hyperparathyroidism. Koizumi M, Komaba H, Nakanishi S, Fujimori A, Fukagawa M, Nephrol Dial Transplant 2012 27 784 790 10.1093/ndt/gfr384 21730210
14. Cinacalcet HCl and concurrent low-dose vitamin D improves treatment of secondary hyperparathyroidism in dialysis patients compared with vitamin D alone: the ACHIEVE study results. Fishbane S, Shapiro WB, Corry DB, Vicks SL, Roppolo M, Rappaport K, Ling X, Goodman WG, Turner S, Charytan C, Clin J Am Soc Nephrol 2008 3 1718 1725 10.2215/CJN.01040308 18945995
15. Serum fibroblast growth factor-23 (FGF-23) levels are independently associated with left ventricular mass and myocardial performance index in maintenance haemodialysis patients. Kirkpantur A, Balci M, Gurbuz OA, Afsar B, Canbakan B, Akdemir R, Ayli MD, Nephrol Dial Transplant 2011 26 1346 1354 10.1093/ndt/gfq539 20813767
16. Clinical relevance of FGF-23 in chronic kidney disease. Seiler S, Heine GH, Fliser D, Kidney Int Supplement 2009 114 34 S42
17. Fibroblast growth factor 23 and mortality among patients undergoing hemodialysis. Gutierrez OM, Mannstadt M, Isakova T, Rauh-Hain JA, Tamez H, Shah A, Smith K, Lee H, Thadhani R, Juppner H, Wolf M, N Engl J Med 2008 359 584 592 10.1056/NEJMoa0706130 18687639
18. The OPTIMA study: assessing a new cinacalcet (Sensipar/Mimpara) treatment algorithm for secondary hyperparathyroidism. Messa P, Macario F, Yaqoob M, Bouman K, Braun J, von Albertini B, Brink H, Maduell F, Graf H, Frazao JM, Bos WJ, Torregrosa V, Saha H, Reichel H, Wikie M, Zani VJ, Molemans B, Carter D, Locatelli F, Clin J Am Soc Nephrol 2008 3 36 45 10.2215/CJN.03591006 18178780
19. Simultaneous control of PTH and CaxP Is sustained over three years of treatment with cinacalcet HCl. Sprague SM, Evenepoel P, Curzi MP, Gonzalez MT, Husserl FE, Kopyt N, Sterling LR, Mix C, Wong G, Clin J Am Soc Nephrol 2009 4 1465 1476 10.2215/CJN.06141108 19696213
20. Fibroblast growth factor 23 is a counter-regulatory phosphaturic hormone for vitamin D. Liu S, Tang W, Zhou J, Stubbs JR, Luo Q, Pi M, Quarles LD, J Am Soc Nephrol 2006 17 1305 1315 10.1681/ASN.2005111185 16597685
21. Intravenous calcitriol therapy increases serum concentrations of fibroblast growth factor-23 in dialysis patients with secondary hyperparathyroidism. Nishi H, Nii-Kono T, Nakanishi S, Yamazaki Y, Yamashita T, Fukumoto S, Ikeda K, Fujimori A, Fukagawa M, Nephron Clin Pract 2005 101 94 c99 10.1159/000086347 15956805
22. FGF23/Klotho axis: phosphorus, mineral metabolism and beyond. Donate-Correa J, Muros-de-Fuentes M, Mora-Fernandez C, Navarro-Gonzalez JF, Cytokine Growth Factor Rev 2012 23 37 46 10.1016/j.cytogfr.2012.01.004 22360923
23. Effect of cinacalcet on cardiovascular disease in patients undergoing dialysis. Chertow GM, Block GA, Correa-Rotter R, Drueke TB, Floege J, Goodman WG, Herzog CA, Kubo Y, London GM, Mahaffey KW, Mix TC, Moe SM, Trotman ML, Wheeler DC, Parfrey PS, N Engl J Med 2012 367 2482 2494 23121374
24. Fibroblast growth factor-23 relationship to dietary phosphate and renal phosphate handling in healthy young men. Ferrari SL, Bonjour JP, Rizzoli R, J Clin Endocrinol Metab 2005 90 1519 1524 15613425
25. Dietary phosphorus regulates serum fibroblast growth factor-23 concentrations in healthy men. Antoniucci DM, Yamashita T, Portale AA, J Clin Endocrine Metab 2006 91 3144 3149 10.1210/jc.2006-0021